

Variant: *NM_000059.4(BRCA2):c.566A>G (p.Asp189Gly)*

Version: 1.0

CA022922 [↗](#)

37986 (ClinVar) [↗](#)

Gene: BRCA2 ([HGNC:675](#))

Condition: BRCA2-related cancer predisposition ([MONDO:0700269](#))

Inheritance Mode: Autosomal dominant inheritance

UUID: 349e363d-bab4-4401-844c-efef434e6f57

Approved on: 2026/7/15

Published on: 2026/7/15

HGVS expressions

NM_000059.4(BRCA2):c.566A>G (p.Asp189Gly)

NM_000059.4:c.566A>G

NC_000013.11:g.32326548A>G

CM000675.2:g.32326548A>G

NC_000013.10:g.32900685A>G

CM000675.1:g.32900685A>G

NC_000013.9:g.31798685A>G

NG_012772.3:g.16069A>G

ENST00000470094.2:c.566A>G

ENST00000528762.2:c.566A>G

ENST00000530893.7:c.197A>G

ENST00000665585.2:c.566A>G

ENST00000666593.2:c.566A>G

ENST00000700202.2:c.566A>G

ENST00000700200.1:n.437A>G

ENST00000700201.1:c.*345A>G

ENST00000380152.8:c.566A>G

ENST00000544455.6:c.566A>G

ENST00000614259.2:c.566A>G

ENST00000680887.1:c.566A>G

ENST00000380152.7:c.566A>G

ENST00000530893.6:n.764A>G

ENST00000544455.5:c.566A>G

ENST00000614259.1:n.566A>G

NM_000059.3:c.566A>G

Likely Pathogenic

Met criteria codes **2**

PVS1 **PM2_Supporting**

Not Met criteria codes **1**

PP3

Evidence Links **0**

Expert Panel

ENIGMA BRCA1 and BRCA2 VCEP [↗](#)

Criteria Specification Information

[↗](#) **Criteria Specification:** ClinGen ENIGMA BRCA1 and BRCA2 Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for BRCA2 Version 1.1.0

[↗](#) **Criteria Specification Approval History**

Evidence submitted by expert panel

ENIGMA BRCA1 and BRCA2 VCEP

The c.566A>G variant in BRCA2 is a missense variant predicted to cause substitution of aspartic acid by glycine at amino acid 189 (p. (Asp189Gly)). This variant is absent from gnomAD v4.1 (read depth $\geq 25x$ in >90% samples, PM2_Supporting met). This BRCA2 missense variant has a SpliceAI score of 0.7, predicting an impact on splicing (score threshold ≥ 0.2) (PP3 not applied because a PVS1 code is met). This variant is reported to result in aberrant mRNA splicing. Minigene, RT-PCR, and RNAseq demonstrated that the variant causes deletion of part of the exon (r.562_631del), resulting in an out-of-frame transcript. The percent aberrant transcript produced from the variant allele using allele specific assessment with sequence analysis was determined to be >90% (ENIGMA unpublished data, Ambry internal data, Internal lab contributor). Final code strength determined by the rubric: PVS1 (RNA). In summary, this variant meets the criteria to be classified as a Likely pathogenic variant for BRCA2-related cancer predisposition based on the ACMG/AMP criteria applied as specified by the ENIGMA BRCA1/2 VCEP (PM2_Supporting, PVS1 (RNA)).

Met criteria codes

PVS1			This variant is reported to result in aberrant mRNA splicing. Minigene, RT-PCR, and RNAseq demonstrated that the variant causes deletion of part of the exon (r.562_631del), resulting in an out-of-frame transcript. The percent aberrant transcript produced from the variant allele using allele specific assessment with sequence analysis was determined to be >90% (ENIGMA unpublished data, Ambry internal data, Internal lab contributor). Final code strength determined by the rubric: PVS1 (RNA).
PM2_Supporting			This variant is absent from gnomAD v4.1 (read depth $\geq 25x$ in >90% samples, PM2_Supporting met).

Not Met criteria codes

PP3			This BRCA2 missense variant has a SpliceAI score of 0.7, predicting an impact on splicing (score threshold ≥ 0.2) (PP3 not applied because a PVS1 code is met).
------------	---	---	---

Curation History [↗](#)



 

 

Showing 1 to 1 of 1 rows

--

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.

[ClinGen Terms of Use.](#)

[✕ Powered by BCM's Genboree.](#)